#SPARC is getting ready for a sparkling move #superchartz

Key Levels:
Support: 360 to 350
Resistance: 389, 399, 421
Key Drivers:
Sun Pharma Advanced Research Company Ltd focuses on R&D of pharmaceutical products, earning revenue from license fees, royalties, and R&D services. In FY23, it obtained USFDA approval for Sezaby and filed for NDA of PDP-716 in collaboration with Visiox Pharma. The company primarily targets oncology & neurodegeneration, with 8 pipeline assets in various stages. It has shifted focus from New Drug Delivery Systems to New Chemical Entities, investing heavily in R&D. SPARC is part of the SunPharma Group, with significant corporate backing. It faced an IT security incident in March 2023, though business operations were not directly impacted. The company plans Phase 1 studies for SCD-153 and SBO-154 in FY24 and FY25, respectively, aiming for continued growth through collaborations and new preclinical programs.
Support: 360 to 350
Resistance: 389, 399, 421
Key Drivers:
Sun Pharma Advanced Research Company Ltd focuses on R&D of pharmaceutical products, earning revenue from license fees, royalties, and R&D services. In FY23, it obtained USFDA approval for Sezaby and filed for NDA of PDP-716 in collaboration with Visiox Pharma. The company primarily targets oncology & neurodegeneration, with 8 pipeline assets in various stages. It has shifted focus from New Drug Delivery Systems to New Chemical Entities, investing heavily in R&D. SPARC is part of the SunPharma Group, with significant corporate backing. It faced an IT security incident in March 2023, though business operations were not directly impacted. The company plans Phase 1 studies for SCD-153 and SBO-154 in FY24 and FY25, respectively, aiming for continued growth through collaborations and new preclinical programs.
Dagangan aktif
Broken both the resistance and now again getting started to get the final resistanceRegards
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Regards
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.